Efficacy of the combination of AstraZeneca and Sputnik V vaccines demonstrated

The process began in February 2021, where a total of 50 volunteers have been recruited to date, while recruitment for clinical trials continues.

As RDIF reports in a press release, “Interim analysis of the data shows high safety rates for combined use: there are no serious side effects, and no cases of coronavirus after vaccination. ” Regarding the next month the first data on the immunogenicity of the combined use will be published in the Republic of Azerbaijan.

The Clinical trials of vaccine combinations are being carried out in several countries at the same time as part of a global program: “Vaccination of volunteers is underway in the United Arab Emirates and regulatory approval has been obtained for trials in Russia and Belarus.

Kirill Dmitriev, the executive director of the Russian body, said: “As new strains of coronavirus emerge, partnerships between vaccine manufacturers and combinations of different drugs are playing a key role in successfully fighting the pandemic. “

He added: “Based on the high efficiency of the heterogeneous boost approach, RDIF was the first in the world to initiate partnerships with other manufacturers of coronavirus vaccines. The first of these partnerships was a joint clinical trial with the company AstraZeneca.

Success in Azerbaijan and other countries will allow more effective implementation of Covid-19 vaccination programs and protect the health of people around the world.

Finally, the Managing Director of AstraZeneca in Russia and Eurasia, Irina Panarina, I declare that “Heterogeneous primary booster, in which components of different vaccines are given to a patient, is one of the most promising immunization schedules to study.”. And he concluded: “This is becoming particularly relevant now, as the issue of preventing the spread of new strains of coronavirus infection is vital and the need for revaccination among the population grows as well.”